Información del artículo
Artículo
Opciones para acceder a los textos completos de la publicación Piel. Formación continuada en dermatología
Suscriptor
Comprar
Contactar
Teléfono para suscripciones e incidencias
De lunes a viernes de 9h a 18h (GMT+1) excepto los meses de julio y agosto que será de 9 a 15h
Llamadas desde España
932 415 960
Llamadas desde fuera de España
+34 932 415 960
E-mail
Bibliografía
[1]
R. Taberner, C. Nadal, A. Llambrich, A. Vila, A. Torné.
Motivos de consulta dermatológicos en la población inmigrante y española del área de salud del Hospital Son Llàtzer (Mallorca).
Actas Dermosifiliogr, 101 (2010), pp. 323-329
[2]
R. Ballester Sánchez, R. Botella Estrada.
Factores etiológicos y epidemiológicos de las queratosis actínicas.
Monogr Dermatol, 27 (2014), pp. 11-13
[3]
H. Vázquez Veiga.
Evolución de las queratosis actínicas: de la piel normal al carcinoma y sus posibles metástasis.
Monogr Dermatol, 27 (2014), pp. 21-25
[4]
C. Ferrándiz-Puldio, C. Ferrándiz.
Queratosis actínicas y cáncer cutáneo en inmunodeprimidos.
Monogr Dermatol, 27 (2014), pp. 31-39
[5]
R. Marks, P. Foley, G. Goodman, B.H. Hage, T.S. Selwood.
Spontaneous remission of solar keratoses: The case for conservative management.
Br J Dermatol, 115 (1986), pp. 649-655
[6]
A. Petit.
Les kératoses actiniques sont des kératoses actiniques.
Ann Dermatol Venereol, 135 (2008), pp. 93-96
[7]
A.B. Ackerman, J.M. Mones.
Solar (actinic) keratosis is squamous cell carcinoma.
Br J Dermatol, 155 (2006), pp. 9-22
[8]
A.S. Jonason, S. Kunala, G.J. Price, R.J. Restifo, H.M. Spinelli, J.A. Persing, et al.
Frequent clones of p53-mutated keratinocytes in normal human skin.
Proc Natl Acad Sci USA, 93 (1996), pp. 14025-14029
[9]
Y.T. Jadotte, R.A. Schwartz.
Solar cheilosis: An ominous precursor: Part I diagnostic insights.
J Am Acad Dermatol, 66 (2012), pp. 173-184
[10]
R. Marks.
Who benefits from calling a solar keratosis a squamous cell carcinoma?.
Br J Dermatol, 155 (2006), pp. 23-26
[11]
A. Chia, G. Moreno, A. Lim, S. Shumack.
Actinic keratoses.
Aust Fam Physician, 36 (2007), pp. 539-543
[12]
D.P. Slaughter, H.W. Southwick, W. Smejkal.
Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin.
Cancer, 6 (1953), pp. 963-968
[13]
A. España.
Queratosis actínica y campo de cancerización.
Monogr Dermatol, 27 (2014), pp. 6-10
[14]
G.D. Dakubo, J.P. Jakupciak, M.A. Birch-Machin, R.L. Parr.
Clinical implications and utility of field cancerization.
Cancer Cell Int, 7 (2007), pp. 2-13
[15]
G. Fortuna, M.D. Mignogna.
Oral field cancerization.
CMAJ, 183 (2011), pp. 1622
[16]
L.A. Torezan, C. Festa-Neto.
Cutaneous field cancerization: Clinical, histopathological and therapeutic aspects.
An Bras Dermatol, 88 (2013), pp. 775-786
[17]
R. Sabharwal, A. Mahendra, N.J. Moon, P. Gupta, A. Jain, S. Gupta.
Genetically altered fields in head and neck cancer and second field tumor.
South Asian J Cancer, 3 (2014), pp. 151-153
[18]
M. Aparna, P. Shenai, L. Chatra, K.M. Veena, P.K. Rao, R.V. Prabhu, et al.
Field cancerization. A review.
Arch Med Health Sci, 1 (2013), pp. 136-139
[19]
B. Hu, E. Castillo, L. Harewood, P. Ostano, A. Reymond, R. Dummer, et al.
Multifocal epithelial tumors and field cancerization from loss of mesenchymal CSL signaling.
Cell, 149 (2012), pp. 1207-1220
[20]
V.M. Van Houten, M.P. Tabor, M.W. van den Brekel, J.A. Kummer, F. Denkers, J. Dijkstra, et al.
Mutated p53 as a molecular marker for the diagnosis of head and neck cancer.
J Pathol, 198 (2002), pp. 476-486
[21]
S.B. Garcia, M. Novelli, N.A. Wright.
The clonal origin and clonal evolution of epithelial tumours.
Int J Exp Pathol, 81 (2000), pp. 89-116
[22]
S. Vanharanta, J. Massagué.
Field cancerization: Something new under the sun.
Cell, 149 (2012), pp. 1179-1181
[23]
G.P. Dotto.
Multifocal epithelial tumors and field cancerization: stroma as a primary determinant.
J Clin Invest, 124 (2014), pp. 1446-1453
[24]
B.J. Braakhuis, M.P. Tabor, J.A. Kummer, C.R. Leemans, R.H. Brakenhoff.
A genetic explanation of Slaughter's concept of field cancerization: Evidence and clinical implications.
Cancer Res, 63 (2003), pp. 1727-1730
[25]
G. Jaiswal, S. Jaiswal, R. Kumar, A. Sharma.
Field cancerization: Concept and clinical implications in head and neck squamous cell carcinoma.
J Exp Ther Oncol, 10 (2013), pp. 209-214
[26]
I. Zalaudek, S. Piana, E. Moscarella, C. Longo, E. Zendri, F. Castagnetti, et al.
Morphologic grading and treatment of facial actinic keratosis.
Clin Dermatol, 32 (2014), pp. 80-87
[27]
R.H. Rosen, A.K. Gupta, S.K. Tyring.
Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic keratoses: Rapid lesion necrosis followed by lesion-specific immune response.
J Am Acad Dermatol, 66 (2012), pp. 486-493
[28]
J.C. Moreno.
Terapéutica quirúrgica de las queratosis actínicas: electrocirugía, criocirugía, cirugía convencional, dermoabrasión y peelings.
Monogr Dermatol., 27 (2014), pp. 67-71
[29]
E. Stockfleth.
The paradigm shift in treating actinic keratosis: A comprehensive strategy.
J Drugs Dermatol, 11 (2012), pp. 1462-1467
[30]
S. Vegter, K. Tolley.
A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe.
PLoS One, 9 (2014), pp. e96829
[31]
A. Dodds, A. Chia, S. Shumack.
Actinic keratosis: Rationale and management.
Dermatol Ther (Heidelb), 4 (2014), pp. 11-31
[32]
A.K. Gupta, M. Paquet.
Network meta-analysis of the outcome ‘participant complete clearance’ in nonimmunosuppressed participants of eight interventions for actinic keratosis: A follow-up on a Cochrane review.
Br J Dermatol, 169 (2013), pp. 250-259
[33]
G. Micali, F. Lacarrubba, M.R. Nasca, R.A. Schwartz.
Topical pharmacotherapy for skin cancer: Part I. Pharmacology.
J Am Acad Dermatol., 70 (2014),
